DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Lip GY, Pan X, Kamble S. , et al.
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States.
Int J Clin Pract 2016;
70 (09) 752-763
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.